Robert Guttendorf, PhD
Robert J. Guttendorf, R.Ph, Ph.D. is a Senior Consultant, DMPK, at Aclairo Pharmaceutical Development Group, Inc. in Vienna, VA. Dr. Guttendorf provides scientific, regulatory, strategic planning, and due diligence advice and support for drug discovery and development. He has held leadership positions in small biotech and large pharmaceutical companies, including Director of Discovery and Preclinical Development at Pfizer Global R&D and Parke-Davis Pharmaceutical Research, Scientific Strategy Advisor at Pfizer, Vice President of Pharmacology and Biopharmaceutics at Advancis (Middlebrook) Pharmaceutical Co., and Vice President of Pharmacology and Experimental Therapeutics at Sequoia Pharmaceuticals. He has directed ADME/PK support for discovery through NDA across a variety of therapeutic areas, overseeing numerous nonclinical pharm-tox and clinical pharmacology programs, and a host of regulatory submissions. At Parke-Davis/Pfizer, he helped pioneer the implementation of higher throughput ADME/PK screening approaches in drug discovery and was instrumental in defining best practices for DMPK in drug discovery and development. In addition, he led Pfizer’s Global PDM organization in evaluating and implementing new strategies to enhance the quality and R&D survival of exploratory development candidates. He has presented and published numerous papers on various topics in ADME/PK, including the strategic use of ADME data to improve drug discovery and development. He received a B.S. in Pharmacy from West Virginia University and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky.